GFC Life Science
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
GFC Life Science develops specialty ingredients for cosmetics, including active compounds derived from skin microbiome research and exosome extraction technology, and supplies them to domestic and international cosmetics brands.
It also runs a clinical-testing division that provides efficacy and claims-substantiation testing services to cosmetics manufacturers and marketers, a service required under Korean cosmetics regulations. Listed on KOSDAQ, Korea's tech and small-cap board, the company operates two distinct business lines: materials supply and clinical services.
Summary is AI-generated and may contain errors · figures from DART filings
Korean cosmetics law requires brands to hold certified test data before making efficacy claims in advertising, which underpins the demand for GFC's clinical-testing division.
GFC Life Science in five facts
What does GFC Life Science do?
GFC Life Science develops specialty ingredients for cosmetics, including active compounds derived from skin microbiome research and exosome extraction technology, and supplies them to domestic and international cosmetics brands.
Where is GFC Life Science listed and in which sector?
GFC Life Science (Korean name: 지에프씨생명과학) trades under KRX code 388610 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Materials sector, Chemicals.
How large is GFC Life Science?
Its market capitalisation was US$19M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were GFC Life Science's latest annual revenue and operating profit?
For fiscal year 2025, GFC Life Science reported revenue of US$13.4M, operating profit of US$291.5K and net income of US$419.2K, per its annual report on DART (data retrieved from DART on 2026-06-03). Revenue was up 5.4% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-06-03
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on securities held by executives/major shareholdersOct 19
- Report on large shareholdings (5% rule) (standard)Oct 19
- DisclosureOct 6
- [Amended] DisclosureOct 2
- Results of extraordinary shareholders' meetingOct 2
- DisclosureSep 28
- Proxy solicitation reference documentSep 21
- Notice of general shareholders' meetingSep 17
- Report on securities held by executives/major shareholdersSep 16
- Report on large shareholdings (5% rule) (standard)Sep 16
- Report on securities held by executives/major shareholdersSep 9
- Report on large shareholdings (5% rule) (standard)Sep 9
- [Amended] Half-year report (2026.06)Sep 7
- Report on securities held by executives/major shareholdersSep 4
- Report on large shareholdings (5% rule) (standard)Sep 4
- Treasury share disposal: results report
GFC Life Science disposed of 2,500 treasury common shares to a long-serving employee on 2026-07-23 at US$4.07 per share (US$10.2K total), per a 2026-07-20 board resolution; 10,000 treasury shares (0.19% of shares outstanding) remain, valued at US$109K.
Treasury Shares · Jul 23 - Material event report (treasury share disposal)
GFC Life Science disclosed a plan to sell treasury shares worth US$10.2K, about 0.1% of its market value.
Treasury Shares · Jul 20 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
GFC Life Science reported separate results for FY2025: revenue of US$12.2M (+5.42% year on year), operating profit of US$265K (−77.34% year on year) and net income of US$382K (from a loss a year earlier).
Earnings · Feb 11